Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Immunization
Research conducted at University of Lausanne has provided new information about immunization
September 17th, 2008
Data detailed in 'A soluble hexameric form of CD40 ligand activates human dendritic cells and augments memory T cell response' have been presented. According to recent research published in the journal Vaccine, "A strategy to improve the immunogenicity of candidate vaccines is to trigger the innate immune system. Triggering of CD40 at the surface of dendritic cells (DC) is essential in the induction of an efficient immune response." "Although CD40 agonist antibodies have been shown to be potent inducers of immune responses in experimental models, serious safety concerns have been raised for their use in humans. In addition, the production of soluble functional...
Source: Vaccine Weekly (2008-09-17)
|
